CONCENTRATIONS	6 Months Ended
Jun. 30, 2022
Risks and Uncertainties [Abstract]
CONCENTRATIONS	NOTE 16. CONCENTRATIONS The Company has two products that each comprised more than 10% of total revenues during the three and six month periods ended June 30. These products collectively accounted for 32% and 32% of revenues during the three and six months ended June 30, 2022, respectively, and 36% and 36% during the same periods in 2021, respectively. The Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than 10% of the Company’s total pharmacy sales during the three and six months ended June 30, 2022 and 2021. The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 72% and 73% of active pharmaceutical ingredient purchases during the three and six months ended June 30, 2022, respectively, and 85% and 79% during the same periods in 2021, respectively.

CONCENTRATIONS

6 Months Ended

Jun. 30, 2022

NOTE 16. CONCENTRATIONS

The Company has two products that each comprised more than 10% of total revenues during the three and six month periods ended June 30. These products collectively accounted for 32% and 32% of revenues during the three and six months ended June 30, 2022, respectively, and 36% and 36% during the same periods in 2021, respectively.

The Company sells its compounded formulations to a large number of customers. There were no customers who comprised more than 10% of the Company’s total pharmacy sales during the three and six months ended June 30, 2022 and 2021.

The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 72% and 73% of active pharmaceutical ingredient purchases during the three and six months ended June 30, 2022, respectively, and 85% and 79% during the same periods in 2021, respectively.